Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics
|
March 3, 2017
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis
Kumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
November 23, 2011
Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma
Tatiana Plavina, Melissa Berman, Moses Njenga, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
May 3, 2011
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics
Shalini Gupta, Viswanath Devanarayan, Deborah Finco, et al.
Annals of Neurology
|
October 3, 2014
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, et al.
Multiple Sclerosis and Related Disorders
|
January 21, 2017
Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, et al.
Therapeutic Advances in Neurological Disorders
|
July 2, 2016
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
Joleen T White, Scott D Newsome, Bernd C Kieseier, et al.
The New England Journal of Medicine
|
May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
Gary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 22, 2011
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a
Xiao Hu, Kenneth Olivier, Evelyne Polack, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
July 16, 2013
Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β
Meenu Wadhwa, Meena Subramanyam, Susan Goelz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 7, 2013
Changes to anti-JCV antibody levels in a Swedish national MS cohort
Clemens Warnke, Ryan Ramanujam, Tatiana Plavina, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Journal of Pharmacokinetics and Pharmacodynamics
|
March 3, 2017
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis
Kumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
November 23, 2011
Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma
Tatiana Plavina, Melissa Berman, Moses Njenga, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
May 3, 2011
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics
Shalini Gupta, Viswanath Devanarayan, Deborah Finco, et al.
Annals of Neurology
|
October 3, 2014
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, et al.
Multiple Sclerosis and Related Disorders
|
January 21, 2017
Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, et al.
Therapeutic Advances in Neurological Disorders
|
July 2, 2016
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
Joleen T White, Scott D Newsome, Bernd C Kieseier, et al.
The New England Journal of Medicine
|
May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
Gary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 22, 2011
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a
Xiao Hu, Kenneth Olivier, Evelyne Polack, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
July 16, 2013
Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β
Meenu Wadhwa, Meena Subramanyam, Susan Goelz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 7, 2013
Changes to anti-JCV antibody levels in a Swedish national MS cohort
Clemens Warnke, Ryan Ramanujam, Tatiana Plavina, et al.
Page
of 4